Please use this identifier to cite or link to this item:
http://hdl.handle.net/10668/10607
Title: | Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group. |
Authors: | Franco Pérez, Fernando Lavernia, Javier Aguiar-Bujanda, David Miramón, José Gumá, Josep Álvarez, Rut Gómez-Codina, José Arroyo, Francisco García Llanos, Marta Marin, Miguel Alfaro, Jesus Quero, Cristina Delgado, Mayte Nogales, Esteban Menarguez, Francisco Martinez, Natividad Torrente, Maria Royuela, Ana Abreu, Delvys Provencio, Mariano |
Keywords: | Chemotherapy;Extranodal lymphoma;Immunotherapy;Lumpectomy;Neoplasms of the breast |
metadata.dc.subject.mesh: | Adult Aged Aged, 80 and over Antineoplastic Agents Breast Neoplasms Breast Neoplasms, Male Disease-Free Survival Female Humans Lymph Nodes Lymphoma Lymphoma, Non-Hodgkin Male Middle Aged Prognosis Treatment Outcome |
Issue Date: | 17-Sep-2016 |
Abstract: | Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes. We reviewed 55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated. Of the 55 patients, 96.4% were women with an average age of 69 years. A total of 53 patients corresponded to non-Hodgkin lymphoma (NHL), of whom 36.3% had lymph node involvement upon diagnosis. Of the patients, 58.2% were stage IE, and 41.8% were stage IIE. Treatments received included radiotherapy (36.3%), chemotherapy (85.5%), and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82.2% of complete responses were achieved. OS and progression-free survival at 5 years in NHL patients was 76% and 73%, respectively. Current treatments (chemotherapy, immunotherapy, and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas. |
URI: | http://hdl.handle.net/10668/10607 |
metadata.dc.identifier.doi: | 10.1016/j.clml.2016.09.004 |
Appears in Collections: | Producción 2020 |
Files in This Item:
There are no files associated with this item.
This item is protected by original copyright |
This item is licensed under a Creative Commons License